Abstract: Objective: To explore the incidence, clinical characteristics, diagnosis and treatment of hypercalcemia in patients with malignancies. Methods: The clinical characteristics and survival data of 13 cases of malignancies with hypercalcemia were analyzed. These 13 cases were collected from 1 060 patients with malignancies in our department in the recent 3 years. Blood calcium levels were tested by O-CPC methods with COBASEMIRA automatic biochemical analyzer and were recorded. All of the 13 patients received hydration and transfusion of Bisphosphonates. Nine patients received transfusion of Pamidronate(90mg), 2 patients received Sodium Ibandronate(4mg), and 2 patients received Zoledronic Acid(4mg). Re-sults: The blood calcium levels ranged from 2.82 to 4.37 mmol/L. After treatment of Bisphosphonates, the blood calcium levels reached normal leve1 and the patients' clinical symptoms were improved. But high blood calcium occurred again in 5 patients at 0.5~1 months. The median time of hypercalcemia response was 0.5 months. The median survival of patients with malignancies and hypercalcemia was 1.07 months. COX regression analysis showed that the time of hypercalcemia response might be a factor that could derease relative risk and increase survival time. Conclusion: Hypercalcemia was frequently seen in patients with advanced tumor. It is often related to severe clinical symptoms, rapid disease progress and poor prognosis. It should be diagnosed and treated as early as possible.